Vertex Pharmaceuticals (VRTX) EBIAT (2016 - 2025)
Historic EBIAT for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $1.2 billion.
- Vertex Pharmaceuticals' EBIAT rose 3046.0% to $1.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.0 billion, marking a year-over-year increase of 83808.81%. This contributed to the annual value of $4.0 billion for FY2025, which is 83808.81% up from last year.
- Per Vertex Pharmaceuticals' latest filing, its EBIAT stood at $1.2 billion for Q4 2025, which was up 3046.0% from $1.1 billion recorded in Q3 2025.
- In the past 5 years, Vertex Pharmaceuticals' EBIAT registered a high of $1.2 billion during Q4 2025, and its lowest value of -$3.6 billion during Q2 2024.
- In the last 5 years, Vertex Pharmaceuticals' EBIAT had a median value of $882.4 million in 2021 and averaged $635.1 million.
- Per our database at Business Quant, Vertex Pharmaceuticals' EBIAT surged by 110970.15% in 2022 and then plummeted by 49244.29% in 2024.
- Vertex Pharmaceuticals' EBIAT (Quarter) stood at $770.1 million in 2021, then rose by 6.34% to $818.9 million in 2022, then rose by 18.31% to $968.8 million in 2023, then fell by 5.76% to $913.0 million in 2024, then soared by 30.46% to $1.2 billion in 2025.
- Its last three reported values are $1.2 billion in Q4 2025, $1.1 billion for Q3 2025, and $1.0 billion during Q2 2025.